Forbion Capital Partners
Forbion Capital Partners is a private equity and venture capital firm for making investments in buyouts.
Business Model:
Revenue: $0
Employees: 2-10
Rankings
Industries / Tags:
Detailed Forbion Capital Partners Information
Geographic Data
Address: PO Box 5187
City: Naarden
State: flevoland
Zip: 1410
Country: NL
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Twitter
Linkedin
Crunchbase
Metrics
8,335,511Website Global Rank
447Website Monthly Traffic
Twitter Followers
Description
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion&s;s investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2020 | NorthSea Therapeutics | Series B | 40M |
| 3/2021 | Oxular | Series B | 37M |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 10/2021 | Rectify Pharmaceuticals | Series A | 0 |
| 9/2020 | Inversago Pharma | Series B | 0 |
| 8/2018 | KaNDy Therapeutics | Series C | 32.6M |
| 2/2016 | Akarna | Series B | 15M |
| 11/2011 | Oxyrane | Series D | 26.5M |
| 7/2011 | gIcare Pharma | Series A | 7.4M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 2/2020 | Azafaros | Series A | 27.5M |
| 3/2021 | Gyroscope Therapeutics | Series C | 0 |
| 9/2019 | Achilles Therapeutics | Series B | 120.9M |
| 6/2020 | Prilenia | Series A | 62.5M |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 3/2021 | Amphista Therapeutics | Series B | 0 |
| 6/2021 | VectorY | Seed Round | 0 |
| 10/2004 | FlowMedica | Series C | 0 |
| 5/2010 | Exosome Diagnostics | Series A | 20M |
| 12/2021 | ARMGO,Pharma,Inc. | Series B | 0 |
| 11/2006 | Pieris AG | Series B | 0 |
| 8/2009 | NovoGI | Series F | 0 |
| 1/2003 | Impella Cardiosystems | Venture Round | 40M |
| 12/2011 | arGEN-X | Series B | 43.8M |
| 11/2022 | CatalYm | Series C | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 4/2011 | Bluebird Bio | Series C | 30M |
| 11/2020 | Catalym | Series B | 59.3M |
| 10/2012 | Promedior | Series D | 0 |
| 3/2012 | Promedior | Series D | 21.5M |
| 4/2008 | Transave | Series D | 35M |
| 1/2017 | NeRRe Therapeutics | Series B | 28.6M |
| 3/2022 | Precirix | Series B | 0 |
| 5/2015 | Realeve | Series D | 38M |
| 3/2020 | AM Pharma | Venture Round | 25.4M |
| 3/2009 | BioVex | Venture Round | 40M |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 3/2015 | Rigontec | Series A | 5.2M |
| 5/2023 | Dualyx | Series A | 0 |
| 5/2021 | Numab | Series C | 110.6M |
| 9/2016 | Rigontec | Series A | 16.9M |
| 5/2015 | Replimune Group | Seed Round | 2M |
| 10/2011 | Curetis | Series A | 13.3M |
| 8/2020 | Dyne Therapeutics | Series B | 115M |
| 8/2016 | Catalym | Seed Round | - |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 12/2017 | NorthSea Therapeutics | Series A | 29.4M |
| 9/2010 | Cardoz | Series A | 17.6M |
| 11/2018 | OMEICOS Therapeutics | Series C | 0 |
| 1/2015 | enGene | Series B | 0 |
| 10/2018 | Milestone Pharmaceuticals | Series D | 80M |
| 2/2022 | Complement Therapeutics | Seed Round | 5.7M |
| 11/2018 | Inflazome | Series B | 45.8M |
| 3/2018 | Escalier Biosciences | Series B | 19M |
| 3/2015 | Insmed | Post-IPO Equity | - |
| 6/2012 | Santaris Pharma | Venture Round | 12M |
| 10/2011 | Hookipa Pharma | Series A | 9.6M |
| 3/2023 | Seamless Therapeutics | Seed Round | 0 |
| 1/2021 | Complement Therapeutics | Seed Round | - |
| 7/2017 | Exosome Diagnostics | Series C | 0 |
| 1/2016 | Exosome Diagnostics | Series B | 0 |
| 6/2022 | VectivBio | Post-IPO Equity | 0 |
| 11/2011 | CircuLite | Series D | 30M |
| 3/2009 | Pathway Medical Technologies | Series D | 42.5M |
| 11/2013 | Argos Therapeutics | Series E | 0 |
| 7/2005 | Xention | Series B | 13.3M |
| 10/2001 | Ardana Bioscience | Series A | 20M |
| 9/2014 | Pulmologix | Venture Round | 12.4M |
| 4/2012 | Argos Therapeutics | Series D | 0 |
| 3/2010 | Bluebird Bio | Series B | 35M |
| 8/2017 | Milestone Pharmaceuticals | Series C | 55M |
| 12/2013 | Ario Pharma | Seed Round | 3.1M |
| 3/2014 | Exosome Diagnostics | Series B | 0 |
| 3/2023 | Noema Pharma | Series B | 0 |
| 8/2007 | AM Pharma | Series C | 3.4M |
| 9/2011 | Amakem | Series A | 25.2M |
| 12/2007 | Santaris Pharma | Series C | 30M |
| 3/2005 | Borean Pharma | Series A | 0 |
| 4/2023 | Complement Therapeutics | Series A | 0 |
| 10/2018 | Gotham Therapeutics | Series A | 54M |
| 1/2021 | New Amsterdam Pharma | Series A | 0 |
| 6/2010 | Cytheris | Series D | 15M |
| 3/2010 | Promedior | Series C | 12M |
| 12/2007 | Fovea Pharmaceuticals | Series B | 30M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 7/2013 | UniQure | Private Equity Round | 0 |
| 4/2007 | CircuLite | Series B | 5M |
| 1/2010 | CircuLite | Series C | 32.5M |
| 9/2009 | arGEN-X | Series A | 13.6M |
| 4/2013 | Allecra Therapeutics | Series A | 19.6M |
| 1/2011 | PneumRx | Venture Round | 0 |
| 2/2017 | Prexton Therapeutics | Series B | 31.1M |
| 6/2015 | Realeve | Series D | 43.2M |
| 6/2016 | Allecra Therapeutics | Series B | 24.8M |
| 6/2019 | SANIFIT | Series D | 0 |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 8/2022 | F2G | Private Equity Round | 0 |
| 5/2012 | Mitralign | Series D | 0 |
| 3/2008 | PanGenetics | Series C | 35.1M |
| 11/2021 | Prilenia | Series B | 0 |
| 5/2003 | Acorda Therapeutics | Series B | 55.3M |
| 9/2017 | Replimune Group | Series B | 55M |
| 2/2010 | arGEN-X | Series A | 4.5M |
| 7/2019 | AM Pharma | Series F | 130.1M |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 9/2015 | SANIFIT | Series C | 0 |
| 7/2021 | NeRRe Therapeutics | Series B | 0 |
| 9/2022 | Pheon Therapeutics | Series A | 0 |
| 7/2012 | Bluebird Bio | Series D | 0 |
| 3/2003 | Acadia Pharmaceuticals Inc. | Series F | 25M |
| 11/2014 | Curetis | Series B | 0 |
| 2/2011 | CellNovo | Series B | 48.3M |
| 12/2002 | Transave | Series B | - |
| 9/2015 | Exosome Diagnostics | Series B | 0 |
| 4/2019 | Dyne Therapeutics | Series A | 50M |
| 10/2022 | Inversago Pharma | Series C | 0 |
| 2/2013 | Dezima Pharma | Venture Round | 18.6M |
| 1/2021 | CoviCept Therapeutics | Seed Round | 2.3M |
| 9/2015 | Replimune Group | Series A | 30M |
| 9/2005 | Bioceros | Private Equity Round | - |
| 4/2023 | Complement Therapeutics | Series A | 0 |
| 3/2023 | Seamless Therapeutics | Seed Round | 0 |
| 3/2023 | Noema Pharma | Series B | 0 |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 11/2022 | CatalYm | Series C | 0 |
| 10/2022 | Inversago Pharma | Series C | 0 |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 9/2022 | Pheon Therapeutics | Series A | 0 |
| 8/2022 | F2G | Private Equity Round | 0 |
| 6/2022 | VectivBio | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
